الصفحة الرئيسية>>UT-B-IN-1

UT-B-IN-1

رقم الكتالوجGC70608

UT-B-IN-1 (UTBINH-14) هو مثبط قابل للعكس، تنافسي وانتقائي لناقل اليوريا B (UT-B) مع قيم IC50 من 10 و 25 نانومتر بالنسبة للبشر والفئران UT-B على التوالي.

Products are for research use only. Not for human use. We do not sell to patients.

UT-B-IN-1 التركيب الكيميائي

Cas No.: 892742-76-6

الحجم السعر المخزون الكميّة
1 mg
144٫00
متوفر
5 mg
360٫00
متوفر
10 mg
576٫00
متوفر

Tel:(909) 407-4943 Email: sales@glpbio.com


مراجعات العميل

بناء على آراء العملاء.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents
UT-B-IN-1 (UTBINH-14) is a reversible, competitive and selective urea transporter-B (UT-B) inhibitor with IC50 values of 10 and 25 nM for human and mouse UT-B, respectively. UT-B-IN-1 shows low toxicity and high selectivity for UT-B over UT-A isoforms. UT-B-IN-1 increases urine output and reduces urine osmolality of mice. UT-B-IN-1 can be used for diuretic mechanism research.

UT-B-IN-1 (1-1000 nM) inhibits urea efflux in erythrocytes preloaded with urea with an IC50 value of 26.7 nM[1].
UT-B-IN-1 inhibits water transport in AQP1-null erythrocytes[1].
UT-B-IN-1 (0-10 μM;24 h) shows no cytotoxicity to MDCK cells[1].

UT-B-IN-1 (300 μg; i.p., once) increases urine output and reduces urine osmolality in mice with free access to water and food[1].

References:
[1]. Yao C, et al. Triazolothienopyrimidine inhibitors of urea transporter UT-B reduce urine concentration. J Am Soc Nephrol. 2012 Jul;23(7):1210-20.

مراجعات

Review for UT-B-IN-1

Average Rating: 5 ★★★★★ (Based on Reviews and 30 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for UT-B-IN-1

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.